Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
471
Views
19
CrossRef citations to date
0
Altmetric
Original Article: Clinical

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience

Khalil SalehHematology Department, Gustave Roussy Cancer Campus, Villejuif, France; Correspondence[email protected]
,
Alina DanuHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Serge KoscielnyBiostatistics Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Clémence LegoupilBiostatistics Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Sylvain PilorgeHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Cristina Castilla-LlorenteHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
David GhezHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Julien LazaroviciHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Jean-Marie MichotHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Nadine Khalife-SalehHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Valerie LapierreHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Kamelia AlenxandrovaBiostatistics Department, Gustave Roussy Cancer Campus, Villejuif, France;
,
Julia Arfi-RoucheRadiology Department, Gustave Roussy Cancer Campus, Villejuif, France
,
Jean-Henri BourhisHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
&
Vincent RibragHematology Department, Gustave Roussy Cancer Campus, Villejuif, France;
show all
Pages 2580-2587 | Received 18 Jun 2017, Accepted 30 Oct 2017, Published online: 22 Nov 2017

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Marie-Élaine Plante, Xue Feng & Jean-Samuel Boudreault. (2023) Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation. Leukemia & Lymphoma 64:7, pages 1234-1242.
Read now
Alexander Glover, Christopher P. Fox, Andrew McMillan, Amy Beech, Nicholas Martinez-Calle, Catherine Griffiths, Faith Richardson, Nigel Russell & Mark J. Bishton. (2020) A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma. Leukemia & Lymphoma 61:14, pages 3529-3531.
Read now

Articles from other publishers (17)

Alison M. Gulbis & Whitney D. Wallis. 2024. Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Manual of Hematopoietic Cell Transplantation and Cellular Therapies 125 143 .
Ran Wu & Liyuan Ma. (2023) BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transplantation 32.
Crossref
Christian Rausch, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis & Thomas Pabst. (2022) Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. Journal of Clinical Medicine 11:18, pages 5378.
Crossref
Tanja Stoffel, Ulrike Bacher, Yara Banz, Michael Daskalakis, Urban Novak & Thomas Pabst. (2022) BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study. Journal of Clinical Medicine 11:13, pages 3748.
Crossref
Aysun Halacoglu & Songul Serefhanoglu. (2021) A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients. Indian Journal of Hematology and Blood Transfusion 38:1, pages 92-98.
Crossref
Naif I. AlJohani, Momen Nasani, Hosam E. Ahmed, Jalil Ur Rehman, Azhar Nawaz, Zayed Alzahrani & Bassim Albeirouti. (2021) Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study. Hematology/Oncology and Stem Cell Therapy 14:4, pages 327-335.
Crossref
Logan Hahn, Hyun Lim, Tanner Dusyk, Waleed Sabry, Mohamed Elemary, Julie Stakiw, Pat Danyluk & Mark Bosch. (2021) BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Scientific Reports 11:1.
Crossref
Jessica Stokes, Megan S. Molina, Emely A. Hoffman, Richard J. Simpson & Emmanuel Katsanis. (2021) Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation. Cancers 13:7, pages 1702.
Crossref
Hervé Ghesquières, Cécile Dalban, Emmanuelle Nicolas‐Virelizier, Fabrice Jardin, Fabien Le Bras, Steven Le Gouill, Olivier Casasnovas, Séraphine Vizoso, Caroline Hernandez, Séverine Metzger, David Pérol & Guillaume Cartron. (2021) BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres † . British Journal of Haematology 192:3.
Crossref
Eren GUNDUZ, Hava ÜSKÜDAR TEKE, Cengiz BAL & Tuba BULDUK. (2020) Lenfomada Otolog Kök Hücre Nakli Hazırlama Rejimi Olarak Beam ve Bucye Protokollerinin Karşılaştırılması. OSMANGAZİ JOURNAL OF MEDICINE.
Crossref
Thomas Hueso, Thomas Gastinne, Sylvain Garciaz, Emmanuelle Tchernonog, Caroline Delette, René-Olivier Casasnovas, Eric Durot, Roch Houot, Benoît Tessoulin, Olivier Tournilhac, Sandra Malak, Emmanuel Gyan, Luc-Matthieu Fornecker, Julie Abraham, Baptiste Delapierre, Frédéric Peyrade, Richard Lemal, Rémy Gressin, Sylvain Chantepie, Cécile Borel, Rémy Morello, Krimo Bouabdallah, Ahmad Ibrahim, Reda Bouabdallah, Steven Le Gouill & Gandhi Damaj. (2020) Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplantation 55:6, pages 1076-1084.
Crossref
Stanislav Sergeevich Shklyaev, N.A. Falaleeva, T.I. Bogatyreva, A.Yu. Terekhova & M.A. Danilova. (2020) Bendamustine in the Treatment of Relapsed/Refractory Hodgkin’s Lymphoma: Literature Review and Clinical Experience. Clinical oncohematology 13:2, pages 136-149.
Crossref
Irene Prediletto, Sarah A. Farag, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Rachel Brégy, Thilo Zander, Daniel Betticher, Thomas Egger, Urban Novak & Thomas Pabst. (2019) High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone Marrow Transplantation 54:12, pages 1923-1925.
Crossref
Parastoo B. Dahi, Hillard M. Lazarus, Craig S. Sauter & Sergio A. Giralt. (2018) Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transplantation 54:7, pages 943-960.
Crossref
Erica S. Tsang, Diego Villa, Federica Loscocco, Giuseppe Visani, Maryse Power, Barbara Guiducci, Cristina Clissa, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, David Sanford, Stephen H. Nantel, Laurie H. Sehn, David W. Scott, Kerry J. Savage, Joseph M. Connors, Alina S. Gerrie & Alessandro Isidori. (2018) High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplantation 54:3, pages 481-484.
Crossref
. (2019) Antineoplastics. Reactions Weekly 1738:1, pages 32-32.
Crossref
Thomas Noesslinger, Michael Panny, Ralph Simanek, Michaela Moestl, Alexandra Boehm, Elisabeth Menschel, Elisabeth Koller & Felix Keil. (2018) High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. European Journal of Haematology 101:3, pages 326-331.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.